chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular
Clinical narrative: Early mensuration and started bleeding both times the very next day for a few days and then it stopped; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Apr2021 at 13:00 (at the age of 40-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08May2021 at 12:00 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included attention deficit hyperactivity disorder (ADHD). The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (ADDERALL) 30 mg once a day (1Xday), melatonin (MANUFACTURER UNKNOWN) and unspecified multivitamins; all for unknown indications from an unknown date and unknown if ongoing. On Apr2021, besides the normal side effects both shorts, the patient experienced early mensuration and started bleeding both times the very next day for a few days and then it stopped. The patient was assuming it was from the vaccine and she could not put in both dates but this happened with the first and second vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of events besides the normal side effects both shorts, the patient experienced early mensuration and started bleeding both times. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event early mensuration and started bleeding both times was recovering at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.            .
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Breast mass, Rash
Clinical narrative: "I" received the second Pfizer vaccine on April 29.On the evening of Saturday May 1, "I" noticed a rash beginning to form around "my" right nipple; A small lump under "my" right nipple.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO172) via an unspecified route of administration in the left arm on 29Apr2021 at 11:30(at the age of 55-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ERB729) via an unspecified route of administration in the left arm on 08Apr2021 at 14:00(at the age of 55-years-old) as a single dose for COVID-19 immunisation. On 01May2021 at 20:00, in the evening, the patient noticed a rash which began to form around his right nipple and small lump under his right nipple. By 03May2021, the rash and the lump had tripled in size, on 05May2021, the rash and lump had begun to subside. On 06May2021, patient met with his doctor for a physical. The doctor said that was possible the rash and lump were a side effect of the vaccine. On 07May2021, the rash and the lump are almost gone. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash beginning to form around the right nipple and a small lump under right nipple was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Haemorrhoids
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 29Mar2021(at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included obesity and allergy to macadamia nuts. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included buspirone (MANUFACTURER UNKNOWN), adults vitamins and NSRI prescription from an unknown date for unspecified indication and unknown if ongoing. The patient previously took cefalexin (KEFLEX) and codeine (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 08Mar2021(at the age of 50-years-old) as a single dose for COVID-19 immunisation. On 29Mar2021, several hours after the vaccination the patient experienced hemorrhoids and lasted roughly two days, then resolved. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the reported event and included treatment with the product preparation H cream. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event hemorrhoids was recovered on 31Mar2021, after the duration of 2 days. No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Influenza like illness, Nausea
Clinical narrative: 12 hours later flu like symptoms; Chills; Bodyache; Fever up to 102 degrees for next 24 hours; Followed by severe headache and nausea that lasted next 48 hours straight. Day 4 and 5 on and off headaches; Nausea that lasted next 48 hours straight; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 03May2021 at 18:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer in 2014, smoker, anxiety and chronic inflammatory lung disease (COPD). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included alprazolam (XANAX), ascorbic acid (VITAMIN C) and zinc (MANUFACTURER UNKNOWN); all from unknown date for unknown indication and unknown if ongoing. The patient previously took hydrocodone bitartrate; paracetamol (VICODIN) and experienced adverse effects. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 19Apr2021 at 17:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. On 04May2021 at 05:00, 12 hours later the patient experienced flu like symptoms, bodyache, chills, fever up to 102 degrees (units unspecified) for next 24 hours. Followed by severe headache and nausea that lasted next 48 hours straight. Day 4 and 5 she had on and off headaches. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events flu like symptoms, bodyache, chills, fever up to 102 degrees (units unspecified) for next 24 hours was resolved with sequelae on 05May2021. The clinical outcome of the events severe headache and nausea that lasted next 48 hours straight; day 4 and 5 had on and off headaches was resolved with sequelae on an unknown date in May2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: 12 hours later flu like symptoms; Chills; Bodyache; Fever up to 102 degrees for next 24 hours; Followed by severe headache and nausea that lasted next 48 hours straight. Day 4 and 5 on and off headaches; Nausea that lasted next 48 hours straight; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 03May2021 at 18:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer in 2014, smoker, anxiety and chronic inflammatory lung disease (COPD). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included alprazolam (XANAX), ascorbic acid (VITAMIN C) and zinc (MANUFACTURER UNKNOWN); all from unknown date for unknown indication and unknown if ongoing. The patient previously took hydrocodone bitartrate; paracetamol (VICODIN) and experienced adverse effects. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 19Apr2021 at 17:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. On 04May2021 at 05:00, 12 hours later the patient experienced flu like symptoms, bodyache, chills, fever up to 102 degrees (units unspecified) for next 24 hours. Followed by severe headache and nausea that lasted next 48 hours straight. Day 4 and 5 she had on and off headaches. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events flu like symptoms, bodyache, chills, fever up to 102 degrees (units unspecified) for next 24 hours was resolved with sequelae on 05May2021. The clinical outcome of the events severe headache and nausea that lasted next 48 hours straight; day 4 and 5 had on and off headaches was resolved with sequelae on an unknown date in May2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: After receiving vaccine, started to experience hives that come and go. They are welt-like and tend to appear after showering and in the evenings. They are centered around lower back and waist area,  but occasionally appear on neck and arms; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 04May2021 at 17:15 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient was allergic to shellfish. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ethinylestradiol, norgestimate (TRI-SPRINTEC), taken for birth control from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 13Apr2021 at 17:15 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. On 06May2021 at 22:30, after receiving the vaccine, the patient started to experience hives that came and went. They were welt-like and had tend to appear after showering and in the evenings. They were centered around her lower back and waist area, but occasionally appeared on her neck and arms. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event after receiving the vaccine experienced hives that came and went, they were welt-like and tend to appear after showering and in the evenings and centered around her lower back and waist area, but occasionally appeared on her neck and arms was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Fatigue, Feeling abnormal, Flatulence, Influenza like illness
Clinical narrative: Mostly long term gastrointestinal gas; Nausea; Exhaustion; Some brain fog; Almost flue like; Diarrhea, symptoms not getting better; No able to function as normal.; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 28Apr2021 at 15:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included environment illness and chronic inflammation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received pentazocine (TALWIN), codeine (MANUFACTURER UNKNOWN), bupropion hydrochloride (WELLBUTRIN), cortisone (MANUFACTURER UNKNOWN) and fluoroquinolone (MANUFACTURER UNKNOWN), for unknown indication from an unknown date and experienced drug allergy. On 30Apr2021, the patient experienced mostly long term gastrointestinal gas and nausea, exhaustion, some brain fog. Overall, in well, almost flu like. Diarrhea, symptoms were not getting better and not able to function as normal. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events mostly long term gastrointestinal gas, nausea, exhaustion, some brain fog (foggy feeling in head), flu like and diarrhea was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Loss of personal independence in daily activities, Nausea
Clinical narrative: Mostly long term gastrointestinal gas; Nausea; Exhaustion; Some brain fog; Almost flue like; Diarrhea, symptoms not getting better; No able to function as normal.; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 28Apr2021 at 15:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included environment illness and chronic inflammation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received pentazocine (TALWIN), codeine (MANUFACTURER UNKNOWN), bupropion hydrochloride (WELLBUTRIN), cortisone (MANUFACTURER UNKNOWN) and fluoroquinolone (MANUFACTURER UNKNOWN), for unknown indication from an unknown date and experienced drug allergy. On 30Apr2021, the patient experienced mostly long term gastrointestinal gas and nausea, exhaustion, some brain fog. Overall, in well, almost flu like. Diarrhea, symptoms were not getting better and not able to function as normal. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events mostly long term gastrointestinal gas, nausea, exhaustion, some brain fog (foggy feeling in head), flu like and diarrhea was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Dyspnoea, Musculoskeletal chest pain
Clinical narrative: Shortness of breath; Tight chest; chest muscle pain.; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 30Apr2021 at 08:45(at the age of 35-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included unspecified prenatals from an unknown date for an unknown indication and unknown if ongoing. On 07May2021 at 08:00, the patient experienced shortness of breath, tight chest and chest muscle pain. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events shortness of breath, tight chest and chest muscle pain were not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling hot, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Left arm was  injection location, was very sore; Left arm is the injection location, swollen; Left arm was the injection location, red; Left arm was the injection location, hot to the touch.; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the left arm on 04May2021 at 13:00 (at the age of 58-year-old) as a 0.3 mL single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 13Apr2021 at 13:00 (at the age of 58-year-old) as a 0.3 mL single dose for COVID-19 immunisation. On 07May2021, the patient experienced left arm, which was her injection location, was very sore, swollen, red and hot to the touch. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events left arm which was injection location, was very sore, swollen, red and hot to the touch was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Chills, Feeling abnormal, Inappropriate schedule of product administration, Pain
Clinical narrative: Severe chills; Body aches; Musculoskeletal issues in upper back; Dose 1: 08Apr2021; Dose 2: 22Apr2021; Have not felt like myself since dose 2; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0175) via an unspecified route of administration in the left arm on 22Apr2021 at 12:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included gastrointestinal ischemia. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant therapies were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 08Apr2021 at 12:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On 22Apr2021, the patient had not felt like herself since dose 2. On 23Apr2021 at 22:45 the patient experienced severe chills, body aches and musculoskeletal issues in upper back. The patient also reported that chiropractor also informed her that he has seen several patients develop strange musculoskeletal issues following dose 1 or 2 of the vaccine. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of not felt like herself since dose 2, severe chills, body aches and musculoskeletal issues in upper back and included treatment under chiropractor's care and taking anti-inflammatory medication. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events not felt like herself since dose 2, severe chills, body aches and musculoskeletal issues in upper back were recovered with sequelae.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Chills, Dizziness, Headache
Clinical narrative: High fever; Chills; Throbbing pain through the entire arm radiating to the wrist ( left arm)/ Sore mid part of body; Sore throat; Swollen neck lymph nodes; Excessive sweating; Headache; Insomnia; Lower back pain; Sensitive to touch mid part of the body; Muscle pain; Joint pain; Excessive vaginal discharge; Dizziness; Throbbing pain through the entire arm; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05May2021 at 11:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included unspecified contraceptive pills from unknown date and unknown if ongoing. The patient did not receive other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 14Apr2021 at 14:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 23:30, the patient experienced high fever, chills, throbbing pain through the entire arm radiating to the wrist (left arm), sore throat, swollen neck lymph nodes, excessive sweating, headache, insomnia, lower back pain, sore, sensitive to touch mid part of the body, muscle and joint pain, excessive vaginal discharge, and dizziness. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events high fever, chills, throbbing pain through the entire arm radiating to the wrist (left arm), sore throat, swollen neck lymph nodes, excessive sweating, headache, insomnia, lower back pain, sore, sensitive to touch mid part of the body, muscle and joint pain, excessive vaginal discharge, and dizziness was resolving at the time of this report.  No follow-up attempts are required, information about lot/batch number cannot be obtained. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperaesthesia, Hyperhidrosis, Insomnia, Lymphadenopathy, Myalgia
Clinical narrative: High fever; Chills; Throbbing pain through the entire arm radiating to the wrist ( left arm)/ Sore mid part of body; Sore throat; Swollen neck lymph nodes; Excessive sweating; Headache; Insomnia; Lower back pain; Sensitive to touch mid part of the body; Muscle pain; Joint pain; Excessive vaginal discharge; Dizziness; Throbbing pain through the entire arm; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05May2021 at 11:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included unspecified contraceptive pills from unknown date and unknown if ongoing. The patient did not receive other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 14Apr2021 at 14:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 23:30, the patient experienced high fever, chills, throbbing pain through the entire arm radiating to the wrist (left arm), sore throat, swollen neck lymph nodes, excessive sweating, headache, insomnia, lower back pain, sore, sensitive to touch mid part of the body, muscle and joint pain, excessive vaginal discharge, and dizziness. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events high fever, chills, throbbing pain through the entire arm radiating to the wrist (left arm), sore throat, swollen neck lymph nodes, excessive sweating, headache, insomnia, lower back pain, sore, sensitive to touch mid part of the body, muscle and joint pain, excessive vaginal discharge, and dizziness was resolving at the time of this report.  No follow-up attempts are required, information about lot/batch number cannot be obtained. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pain, Pain in extremity, Pyrexia, Vaginal discharge
Clinical narrative: High fever; Chills; Throbbing pain through the entire arm radiating to the wrist ( left arm)/ Sore mid part of body; Sore throat; Swollen neck lymph nodes; Excessive sweating; Headache; Insomnia; Lower back pain; Sensitive to touch mid part of the body; Muscle pain; Joint pain; Excessive vaginal discharge; Dizziness; Throbbing pain through the entire arm; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05May2021 at 11:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included unspecified contraceptive pills from unknown date and unknown if ongoing. The patient did not receive other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 14Apr2021 at 14:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 23:30, the patient experienced high fever, chills, throbbing pain through the entire arm radiating to the wrist (left arm), sore throat, swollen neck lymph nodes, excessive sweating, headache, insomnia, lower back pain, sore, sensitive to touch mid part of the body, muscle and joint pain, excessive vaginal discharge, and dizziness. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events high fever, chills, throbbing pain through the entire arm radiating to the wrist (left arm), sore throat, swollen neck lymph nodes, excessive sweating, headache, insomnia, lower back pain, sore, sensitive to touch mid part of the body, muscle and joint pain, excessive vaginal discharge, and dizziness was resolving at the time of this report.  No follow-up attempts are required, information about lot/batch number cannot be obtained. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Musculoskeletal stiffness, Stomatitis
Clinical narrative: Headache; Chills; Exhaustion; Stiff Neck; Sores on Roof of Mouth; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 22Mar2021 at 18:15 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergy to penicillin from an unknown date and prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Mar2021, the patient experienced headache, chills, exhaustion, stiff neck and sores on roof of mouth. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headache, chills, exhaustion, stiff neck and sores on roof of mouth was resolved with sequelae on an unknown date in 2021. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 12Apr2021 at 12:15 (at the age of 48-years-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site mass, Vaccination site swelling
Clinical narrative: Redness at injection site for 3 full days after the 2nd shot; large bump/swelling at injection site for 3 full days; swelling at injection site for 3 full days; This is a spontaneous report from a non-contactable consumer, the patient. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 03May2021 at 11:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfa allergy (sulfonaminde allergy). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included multivitamins (MANUFACTURER UNKNOWN), colecalciferol (VITAMIN D3) and riboflavin (VITAMIN B2) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 09Apr 2021 at 11:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. On 04May2021 at 12:00, after the second shot the patient experienced redness, large bump and swelling at injection site for 3 full days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events redness, large bump and swelling at injection site for 3 full days was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain, Pyrexia
Clinical narrative: This is a spontaneous report from a non-contactable consumer, the patient. A 56-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167) via an unspecified route of administration in the right arm on 06May2021 at 15:00 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on an unknown date in Apr2021 at 15:00 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. On 07May2021 at 01:00, the patient experienced low grade fever, chills, body aches and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the reported events and included treatment with paracetamol (TYLENOL) from an unknown date. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event low-grade fever, chills, body aches and fatigue was resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Lymph node pain
Clinical narrative: Moderate aches in lower back for about 18 hours; Sore lymph nodes right side only about 16 hours; This is a spontaneous report from a non-contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on 05May2021 at 09:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. The patient did not had any medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0164) via an unspecified route of administration in the left arm on 15Apr2021 at 09:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 09:30, the patient experienced moderate aches in lower back for about 18 hours and sore lymph nodes right side only about 16 hours. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore lymph nodes right side only was resolved on 06May2021 at 01:30, after the duration of 16 hrs and moderate aches in lower back resolved on 06May2021 at 03:30, after the duration of 18 hrs.  No follow-up attempts are possible. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Left supraclavicular lymphadenopathy; This is a spontaneous report from a contactable consumer, the physician. A 61-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an intramuscular route of administration in the left arm on 25Apr2021 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history reported as the patient need to release the information. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included methylphenidate (MANUFACTURER UNKNOWN), venlafaxine (MANUFACTURER UNKNOWN) and rosuvastatin (MANUFACTURER UNKNOWN); all for unknown indication, from an unknown start date and unknown if on going. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 04May2021, the patient experienced left supraclavicular lymphadenopathy, no other lymphadenopathy was found and no other symptoms. The reporter tried to speak to someone at Pfizer to see if this particular side effect has occurred with this vaccine, but was unable to get a person on the telephone. If someone could call him, he told he would appreciate it and given his office contact number. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left supraclavicular lymphadenopathy was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy, SARS-CoV-2 test
Clinical narrative: Axillary lymphadenopathy in same arm as vaccine/ Very painful and red swollen lymph node; Very painful and red swollen lymph node; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 16Apr2021 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any concomitant medications. On 24Apr2021, the patient experienced axillary lymphadenopathy in same arm as vaccine about a week after injection and also experienced very painful and red swollen lymph node. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with unspecified antibiotics and the patient's condition was improving. On 27Apr2021, the patient underwent COVID-19 test (reported as other) and the result was negative. The clinical outcome of the events axillary lymphadenopathy in same arm as vaccine/ very painful and red swollen lymph node and very painful and red swollen lymph node was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Migraine
Clinical narrative: Migraine; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 14Apr2021 at 11:15 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received codeine (MANUFACTURER UNKNOWN) and experienced drug allergy. On 14Apr2021 at 12:00, the patient experienced migraine headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event migraine headache was resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Fatigue, Head discomfort, Paraesthesia, Tremor
Clinical narrative: Extreme fatigue; Chest pressure; Head pressure; Tremors; pins and needles throughout body; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 21Apr2021 at 10:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and irritable bowel syndrome (IBS) and Known allergies to latex. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received ampicillin sodium/sulbactam sodium (UNASYN) for an unknown indication on an unknown date and experienced drug allergy. On 26Apr2021 at 08:00, the patient experienced extreme fatigue, chest pressure, head pressure, tremors and pins and needles throughout body. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme fatigue, chest pressure, head pressure, tremors and pins and needles throughout body was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Gingival erythema, Gingival swelling, Headache
Clinical narrative: Extreme fatigue; Headache; Sore throat; Mouth sores; Diagnosed with lichen planus; gums and palate swollen and red; gums and palate swollen and red; gums and palate swollen and red; gums and palate swollen and red; Aches; Chills; Fever; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 19Apr2021 at 17:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included mono as a teenager. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7S34) via an unspecified route of administration in the left arm on 29Mar2021 at 17:15 (at the age of 51-years-old) as a single dose for COVID-19 immunisation and received hyoscine (SCOPOLAMINE) for an unknown indication on an unknown date and experienced drug allergy. On 20Apr2021, day after 2nd shot, the patient experienced aches, chills and fever and over in 24 hours. On 29Apr2021, 10 days after 2nd shot, the patient experienced gums and palate swollen and red. On 30Apr2021, next day, the patient started with fever, extreme fatigue, headache, sore throat, aches, chills, mouth sores developed next to the negative tests for the following: strep, mono, elevated WBC, COVID, flu A or B and was diagnosed with lichen planus. Now, 7 days later, the patient still had unexplained fever, headache and mouth sores. By the way the patient did not agree with our privacy policy as it relates to anything besides the effects of the vaccine, but she felt this needs to be reported in the public interest. On 03May2021, the patient underwent PCR test (nasal swab) and the result was Negative. The events result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the mouth sores and included treatment with oral steroid. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events aches, chills, fever, gums and palate swollen and red, extreme fatigue, headache, sore throat, mouth sores and lichen planus was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.